Loading patent…
AssigneeCentocor, Inc.
InventorsXiao-Yu Song, Chris Huang, Keying Ma, Bailin Liang, Michael Naso
Estimating the term…
Novel polypeptides (CNGH0010) and antibodies, including specified portions or variants, specific for at least one such CNGH0010 polypeptide, variant, or fragment thereof, as well as nucleic acids encoding such CNGH0010 polypeptides and antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, are useful for therapeutic and diagnostic formulations, administration and devices. The aforesaid polypeptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-CNGH0010 antibodies. The CNGH0010 polypeptides and antibodies are used in modulating or treating at least one CNGH0010-related disease in a cell, tissue, organ, animal, or patient. Such diseases may include, but are not limited to, psoriasis, rheumatoid arthritis, emphysema, asthma, diabetes, autoimmune thyroiditis, inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, different types of dermatitis including allergic dermatitis, contact dermatitis, actinic keratosis, wound healing, scar formation, various renal diseases, various respiratory diseases, various diseases of reproductive organs, such as endometriosis, melanoma, squamous cell carcinoma, ovarian cancer, breast cancer, lung cancer, colon cancer, prostate cancer, renal cell carcinoma, Grave's diseases and other inflammatory and hyperproliferative diseases.
An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, and 10, or an exact complement of said nucleotide sequence.
An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 5, 7, 9, and 11.
An isolated nucleic acid molecule encoding a naturally occurring allelic variant of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 5, 7, 9, and 11.
An isolated nucleic acid molecule comprising a nucleotide sequence having at least 90% identity to any one of SEQ ID NOS:2, 4, 6, 8, and 10, or an exact complement of said nucleotide sequence.
An isolated nucleic acid molecule comprising a nucleotide sequence having at least 70% identity to any one of SEQ ID NOS:2, 4, 6, 8, and 10, or an exact complement of said nucleotide sequence.
An isolated nucleic acid molecule comprising a nucleotide sequence of at least 45 nucleotide residues having at least 90% identity to a portion of any one of SEQ ID NOS:2, 4, 6, 8, and 10, or an exact complement of said nucleotide sequence.
An isolated nucleic acid molecule encoding a fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 5, 7, 9, and 11, wherein the fragment has an amino acid sequence comprising at least 15 consecutive amino acid residues of an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 5, 7, 9, and 11.
A kit comprising (i) a compound hybridizing with a nucleic acid molecule having a nucleotide sequence with at least 95% identity to any of SEQ ID NOS:
An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 5, 7, 9, and 11.
An isolated polypeptide comprising a naturally occurring allelic variant of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 5, 7, 9, and 11.
An isolated polypeptide comprising an amino acid sequence having at least 90% identity to an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 5, 7, 9, and 11.
An isolated polypeptide comprising at least 15 contiguous amino acids of an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 5, 7, 9, and 11.
A method for treating a CNGH0010-related condition in a cell, tissue, organ or animal, comprising contacting or administering to a patient a composition comprising an effective amount of one or more modulator of CNGH0010 nucleic acid molecule or CNGH0010 polypeptide levels or a modulator of CNGH0010 activity in said cell, tissue, organ or animal.
A method for treating an epithelial-related condition in a cell, tissue, organ or animal, comprising contacting or administering to a patient a composition comprising an effective amount of at least one modulator of CNGH0010 nucleic acid molecule or CNGH0010 polypeptide levels or a modulator of CNGH0010 activity in said cell, tissue, organ or animal.
An isolated nucleic acid molecule comprising a nucleotide sequence of nucleotides 101-526 (Exon 1), 786-986 (Exon 2), 1099-1155 (Exon 3), 1763-1813 (Exon 4), 1983-2165 (Exon 5), 3324-3392 (Exon 8), 7590-7637 (Exon 13), 7811-7858 (Exon 14), 10690-10746 (Exon 16), 11393-11440 (Exon 17), 12996-13043 (Exon 19), 13547-13618 (Exon 21), 14679-14702 (Exon 22), 14813-14860 (Exon 23), and 16038-16356 (Exon 25) of SEQ ID NO:1 and, optionally, one or more from the group consisting of nucleotides 2936-2980 (Exon 6), 3615-3665 (Exon 9), 5336-5371 (Exon 10), 6065-6118 (Exon 11), 7391-7450 (Exon 12), 13157-13198 (Exon 20), and 15895-15929 (Exon 24) of SEQ ID NO:
An isolated nucleic acid molecule comprising a nucleotide sequence of nucleotides 101-526 (Exon 1), 786-986 (Exon 2), 1099-1155 (Exon 3), 1763-1813 (Exon 4), 1983-2165 (Exon 5), 3324-3392 (Exon 8),7590-7637 (Exon 13), 7811-7858 (Exon 14), and 10129-10155 (Exon 15) of SEQ ID NO:1 and, optionally, one or more from the group consisting of nucleotides 3615-3665 (Exon 9), 5336-5371 (Exon 10), 6065-6118 (Exon 11), and 7391-7450 (Exon 12) of SEQ ID NO:1, or an exact complement of said nucleotide sequence.
An isolated nucleic acid molecule comprising a nucleotide sequence of nucleotides 3149-3205 (Exon 7), 3324-3392 (Exon 8), 7590-7637 (Exon 13), 7811-7858 (Exon 14), 10690-10746 (Exon 16), 11393-11440 (Exon 17), 12996-13043 (Exon 19), 13547-13618 (Exon 21), 14679-14702 (Exon 22), 14813-14860 (Exon 23), and 16038-16356 (Exon 25) of SEQ ID NO:1 and, optionally, one or more from the group consisting of nucleotides 3615-3665 (Exon 9), 5336-5371 (Exon 10), 6065-6118 (Exon 11), 7391-7450 (Exon 12), 13157-13198 (Exon 20), and 15895-15929 (Exon 24) of SEQ ID NO:1, or an exact complement of said nucleotide sequence.
An isolated nucleic acid molecule comprising a nucleotide sequence of nucleotides 3149-3205 (Exon 7), 3324-3392 (Exon 8), 7590-7637 (Exon 13), 7811-7858 (Exon 14), and 10129-10155 (Exon 15) of SEQ ID NO:1 and, optionally, one or more from the group consisting of nucleotides 3615-3665 (Exon 9), 5336-5371 (Exon 10), 6065-6118 (Exon 11), and 7391-7450 (Exon 12) of SEQ ID NO:
An isolated nucleic acid molecule comprising a truncated CNGH0010 nucleotide sequence containing one or more from the group consisting of nucleotides 1983-2076 (Exon Sa), 2117-2165 (Exon 5b), 3168-3197 (Exon 7a), and 3189-3393 (Exon 8a) of SEQ ID NO:1.
Any invention described herein.
Dependencies are inferred from the claim text.